Compare Capri Holdings Ltd (CPRI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Neurocrine Biosciences Inc — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.64B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 8.9× Capri Holdings Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CPRI | NBIX | |
|---|---|---|
Market Cap | $1.64B | $14.60B |
Volume | 1,891,363 | 1,075,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $185.50 |
52-Week Low | $12.71 | $123.10 |
Typical Hold Time | 41 Days | 23 Days |
Enterprise Value | $2.92B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up slightly by 0.07% today, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined to $4.44 billion in 2025, and net income was negative $1.18 billion, though 2026 projections show a return to profitability. The company's balance sheet shows total assets of $5.21 billion against liabilities of $4.84 billion, with a high ROE of 252.89% but modest net income margin of 4.44%.
The outlook is mixed: analyst consensus is a Buy with a $20.57 price target, implying significant upside, but recent news highlights turnaround risks and a lowered 2027 sales view. Key risks include Michael Kors brand weakness and competitive pressures in the luxury sector. Cash flow trends show consistent negative net cash flow, adding to execution concerns amid efforts to revitalize brands.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
